Abstract
Multi-drug and extensively drug-resistant tuberculosis (MDR/XDR-TB) are considered a serious threat for TB control and elimination. The outcome of these patients is still largely unsatisfactory as of today, with treatment success rates being consistently below 50% at global level. The World Health Organization (WHO) recommends that management of MDR-TB cases is supported by a specialized team, including complementary medical professionals able to cover several perspectives (clinical, both for adults and children; surgical; radiological; public health; psychological; nursing, among others). Implementation of such a body (known as Consilium in most of the former Soviet Union countries) is often a pre-requisite to apply for international TB control funding and concessionally priced medicines to treat M/XDR-TB cases. The primary objective of the ERS/WHO TB Consilium is to provide clinical consultation for drug-resistant TB and other difficult-to-treat TB cases, including co-infection with HIV and paediatric cases. Through technical guidance to clinicians managing complex TB cases, the main contribution and outcome of the initiative will be a public health response aimed at achieving correct treatment of affected patients and preventing further development of drug resistance. The Consilum's secondary objective is to ensure monitoring and evaluation of clinical practices on the ground (diagnosis, treatment and prevention).
| Original language | English |
|---|---|
| Pages (from-to) | 156-160 |
| Number of pages | 5 |
| Journal | International Journal of Infectious Diseases |
| Volume | 32 |
| DOIs | |
| Publication status | Published - Mar 1 2015 |
Fingerprint
Keywords
- Clinical management
- Drug resistance
- ERS/WHO Consilium
- MDR-TB
- Prevention
- XDR-TB
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Medicine(all)
Cite this
Supporting clinical management of the difficult-to-treat TB cases : The ERS-WHO TB Consilium. / D'Ambrosio, Lia; Tadolini, Marina; Centis, Rosella; Duarte, Raquel; Sotgiu, Giovanni; Aliberti, Stefano; Dara, Masoud; Migliori, Giovanni Battista.
In: International Journal of Infectious Diseases, Vol. 32, 01.03.2015, p. 156-160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Supporting clinical management of the difficult-to-treat TB cases
T2 - The ERS-WHO TB Consilium
AU - D'Ambrosio, Lia
AU - Tadolini, Marina
AU - Centis, Rosella
AU - Duarte, Raquel
AU - Sotgiu, Giovanni
AU - Aliberti, Stefano
AU - Dara, Masoud
AU - Migliori, Giovanni Battista
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Multi-drug and extensively drug-resistant tuberculosis (MDR/XDR-TB) are considered a serious threat for TB control and elimination. The outcome of these patients is still largely unsatisfactory as of today, with treatment success rates being consistently below 50% at global level. The World Health Organization (WHO) recommends that management of MDR-TB cases is supported by a specialized team, including complementary medical professionals able to cover several perspectives (clinical, both for adults and children; surgical; radiological; public health; psychological; nursing, among others). Implementation of such a body (known as Consilium in most of the former Soviet Union countries) is often a pre-requisite to apply for international TB control funding and concessionally priced medicines to treat M/XDR-TB cases. The primary objective of the ERS/WHO TB Consilium is to provide clinical consultation for drug-resistant TB and other difficult-to-treat TB cases, including co-infection with HIV and paediatric cases. Through technical guidance to clinicians managing complex TB cases, the main contribution and outcome of the initiative will be a public health response aimed at achieving correct treatment of affected patients and preventing further development of drug resistance. The Consilum's secondary objective is to ensure monitoring and evaluation of clinical practices on the ground (diagnosis, treatment and prevention).
AB - Multi-drug and extensively drug-resistant tuberculosis (MDR/XDR-TB) are considered a serious threat for TB control and elimination. The outcome of these patients is still largely unsatisfactory as of today, with treatment success rates being consistently below 50% at global level. The World Health Organization (WHO) recommends that management of MDR-TB cases is supported by a specialized team, including complementary medical professionals able to cover several perspectives (clinical, both for adults and children; surgical; radiological; public health; psychological; nursing, among others). Implementation of such a body (known as Consilium in most of the former Soviet Union countries) is often a pre-requisite to apply for international TB control funding and concessionally priced medicines to treat M/XDR-TB cases. The primary objective of the ERS/WHO TB Consilium is to provide clinical consultation for drug-resistant TB and other difficult-to-treat TB cases, including co-infection with HIV and paediatric cases. Through technical guidance to clinicians managing complex TB cases, the main contribution and outcome of the initiative will be a public health response aimed at achieving correct treatment of affected patients and preventing further development of drug resistance. The Consilum's secondary objective is to ensure monitoring and evaluation of clinical practices on the ground (diagnosis, treatment and prevention).
KW - Clinical management
KW - Drug resistance
KW - ERS/WHO Consilium
KW - MDR-TB
KW - Prevention
KW - XDR-TB
UR - http://www.scopus.com/inward/record.url?scp=84922996783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922996783&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2014.12.024
DO - 10.1016/j.ijid.2014.12.024
M3 - Article
C2 - 25809773
AN - SCOPUS:84922996783
VL - 32
SP - 156
EP - 160
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
ER -